First-half net profit of 41 pharmaceutical companies increased by more than 50% year-on-year, with a number of api-related businesses driving growth

"Pharmaceutical Network Market Analysis" At present, the major listed pharmaceutical companies in the first half of 2020 results have been released.
wind statistics show that the A-share pharmaceutical industry 203 listed companies in the semi-annual report, the net profit is in a positive 182, accounting for nearly 90%.
, 92, accounting for 45.32 percent, had net profits of more than 100 million yuan.
addition, Pro Pharmaceuticals, Tianyu shares, Huahai Pharmaceuticals and other 41 pharmaceutical companies, the first half of 2020 net profit growth rate of more than 50%.
, a number of profitable companies were driven by API-related business growth.
Pharmaceuticals is mainly engaged in oral cephalosporin series, oral penicillin series, spiritual series and other raw materials intermediate series production.
first half of this year, the company reported revenue of RMB3,992 million, up 12.46% YoY, and net profit of RMB429 million, up 52.93% YoY.
increase was mainly due to increased sales revenue from API and CDMO (contract research and development production services), year-on-year decrease in expenses and year-on-year increase in gross margin.
, the API business achieved operating income of 3.020 billion yuan, an increase of 15.41% over the same period last year.
pharmaceutical business accounted for 75.65 percent of the company's overall revenue.
, in the first half of this year, Prop Pharmaceuticals' foreign operating income grew by 26.24% year-on-year, well ahead of the growth rate of domestic business during the same period.
Tianyu's 2019 annual report shows that the company's main business is API, pharmaceutical intermediates, and other, accounting for 59.14 percent of revenue, 40.55 percent, 0.27 percent, respectively.
first half of 2020, Tianyu's API sales were 878 million yuan, up 63.14 percent from a year earlier and 23.77 percent from a year earlier.
company's semi-annual report disclosed that its chemical raw materials and intermediate products are mainly sold to Europe, the United States, Japan, South Korea and other countries and regions, the company's self-export rate of products reached 70.37 percent.
company has a complete supply chain of shatan products from intermediates to API production, the scale of production costs advantage is obvious.
it is worth mentioning that Tianyu shares are also continuing to expand the core products of shatan-type API production capacity.
announced in June that it plans to raise no more than 900 million yuan for projects such as an annual output of 3,550 tons of API, an annual output of 1000 tons of shatan main ring and other 19 pharmaceutical intermediate industrialization projects, an annual output of 670 tons of Erexibufuran ketone and other 6 pharmaceutical intermediate technology reform projects and supplementary liquidity, so as to strengthen the company's position as an important supplier of global API.
Huahai Pharmaceuticals is mainly engaged in multi-dose generic drugs, biological drugs, innovative drugs and specialty RAW drugs research and development, production and sales.
's operating income in the first half of this year was RMB3,306 million, up 24.6% YoY, and the net profit attributable to the company was RMB578 million, up 72.77% YoY.
company attributed the sharp increase in first-half net profit from a year earlier to a significant increase in sales of domestic preparations and API.
First, the domestic preparation is mainly with the promotion of centralized procurement, the company relies on the expansion of the alliance region to select opportunities, product market coverage has been rapidly improved;
, the rise in the dollar, loose monetary policy and the improvement of the company's capital have had a positive impact on the company's operations.
is a very basic link in the pharmaceutical industry chain, and its quality is directly related to the quality of medicine.
after a long period of continuous development, at this stage, China is the world's largest producer of API, but also the world's largest exporter of API, occupy an important position in the international market.
In the industry's view, domestic API manufacturers in the international market to maintain competitiveness, on the one hand, should maintain cooperative relations with the industrial chain upstream and downstream enterprises in order to stabilize supply, on the other hand, in the quality of API products to meet supplier requirements, API manufacturers also need to improve technology, process transformation or large-scale production, and constantly reduce costs, to obtain price competitive advantage.